Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MEDIPOST Co., Ltd. (078160.KQ)
Medipost Co., Ltd. is a biotechnology firm dedicated to the creation and manufacturing of stem cell-based products. Its diverse operations are categorized into several divisions: the Cord Blood Bank, which specializes in the collection and storage of newborn umbilical cord stem cells; Stem Cell Therapy, focused on producing allogeneic stem cell pharmaceuticals; Health Functional Food, offering various vitamins and nutritional supplements; and the Import and Distribution of Natural Cosmetics division, responsible for the sales and marketing of natural cosmetic products sourced from Pevonia Inc. Additionally, the company provides comprehensive Healthcare Services, encompassing bizcare, insu-care, affiliate programs, telehealth, and medical devices, accessible via web, mobile, and call centers. Established on June 26, 2000, by Yoon-Sun Yang and Won-Il Oh, Medipost Co., Ltd. is headquartered in Seongnam, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.44% | -23.58% | -49.15% | -37.44% | -15.83% | -18.14% | +49.78% | -10.39% | -57.84% | -69.22% | -35.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+4.3% ★ Q1'26: +1.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-19.6% Q1'26: +43.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-92.4% Q1'26: -48.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-92.3% Q1'26: -91.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-28.3% Q1'26: -40.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+15.0% Q1'26: +14.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.10× Q1'26: -2.31× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
35.10B
est.
|
28.65B
est: 37.80B (-24.2%)
|
42.25B
est: 50.50B (-16.3%)
|
44.38B
est: 51.00B (-13.0%)
|
45.81B
est: 47.60B (-3.8%)
|
48.62B
est: 47.00B (+3.5%)
|
54.86B
est: 53.50B (+2.5%)
|
64.20B
est: 61.00B (+5.2%)
|
68.64B
est: 62.00B (+10.7%)
|
70.66B
est: 70.70B (-0.1%)
|
73.66B
est: 76.50B (-3.7%)
|
82.90B
82.90B – 82.90B
+8.4% YoY
|
| EBITDA |
-5.55B
est.
|
-11.03B
est: -5.98B (-84.5%)
|
2.48B
est: -7.98B (+131.1%)
|
1.04B
est: -8.06B (+112.9%)
|
2.06B
est: -7.53B (+127.3%)
|
13.34B
est: -7.43B (+279.5%)
|
11.18B
est: -8.46B (+232.1%)
|
-12.05B
est: -9.64B (-25.0%)
|
-19.39B
est: -9.80B (-97.8%)
|
-56.41B
est: -26.97B (-109.2%)
|
-62.04B
est: -29.18B (-112.6%)
|
-31.62B
-31.62B – -31.62B
-8.4% YoY
|
| EBIT |
-8.70B
est.
|
-13.32B
est: -9.37B (-42.1%)
|
-2.01B
est: -12.52B (+83.9%)
|
-3.32B
est: -12.64B (+73.7%)
|
-3.86B
est: -11.80B (+67.3%)
|
8.24B
est: -11.65B (+170.7%)
|
6.28B
est: -13.26B (+147.4%)
|
-17.43B
est: -15.12B (-15.3%)
|
-25.26B
est: -15.37B (-64.4%)
|
-62.43B
est: -32.98B (-89.3%)
|
-67.98B
est: -35.68B (-90.5%)
|
-38.67B
-38.67B – -38.67B
-8.4% YoY
|
| Net Income |
6.67B
est.
|
-5.37B
est: 3.55B (-251.1%)
|
-949.87M
est: 3.79B (-125.1%)
|
-2.01B
est: 1.80B (-211.6%)
|
-14.12B
est: 5.99B (-335.5%)
|
-1.87B
est: -35.10B (+94.7%)
|
-683.26M
est: -10.25B (+93.3%)
|
3.07B
est: -37.02B (+108.3%)
|
5.84B
est: 5.99B (-2.6%)
|
-62.52B
est: -34.74B (-80.0%)
|
-85.40B
est: -32.30B (-164.3%)
|
-26.15B
-26.15B – -26.15B
+19.1% YoY
|
| SGA |
14.05B
est.
|
18.51B
est: 15.13B (+22.4%)
|
19.88B
est: 20.21B (-1.6%)
|
24.22B
est: 20.41B (+18.6%)
|
12.98B
est: 19.05B (-31.8%)
|
21.66B
est: 18.81B (+15.2%)
|
23.57B
est: 21.41B (+10.1%)
|
35.02B
est: 24.41B (+43.4%)
|
19.76B
est: 24.81B (-20.4%)
|
20.67B
est: 21.99B (-6.0%)
|
—
est: 23.80B (-100.0%)
|
25.79B
25.79B – 25.79B
+8.4% YoY
|
| EPS |
195.59
est.
|
-305.92
est: 104.17 (-393.7%)
|
-53.94
est: 111.20 (-148.5%)
|
-113.85
est: 52.74 (-315.9%)
|
-800.83
est: 175.81 (-555.5%)
|
-107.52
est: -1,029.37 (+89.6%)
|
-37.39
est: -300.64 (+87.6%)
|
167.08
est: -1,085.63 (+115.4%)
|
287.00
est: 175.81 (+63.2%)
|
-1,833.23
est: -886.00 (-106.9%)
|
-2,193.40
est: -824.00 (-166.2%)
|
-667.00
-667.00 – -667.00
+19.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 078160.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
